JP7039582B2 - 活性化可能な抗ｃｔｌａ－４抗体およびその使用 - Google Patents

活性化可能な抗ｃｔｌａ－４抗体およびその使用 Download PDF

Info

Publication number
JP7039582B2
JP7039582B2 JP2019523779A JP2019523779A JP7039582B2 JP 7039582 B2 JP7039582 B2 JP 7039582B2 JP 2019523779 A JP2019523779 A JP 2019523779A JP 2019523779 A JP2019523779 A JP 2019523779A JP 7039582 B2 JP7039582 B2 JP 7039582B2
Authority
JP
Japan
Prior art keywords
antibody
seq
ctla
cancer
activating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019523779A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500016A5 (enExample
JP2020500016A (ja
Inventor
キンバリー・アン・ティプトン
ジェイムズ・ウィリアム・ウエスト
シュリカント・デシュパンデ
ジョン・ジェイ・エンゲルハート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2020500016A publication Critical patent/JP2020500016A/ja
Publication of JP2020500016A5 publication Critical patent/JP2020500016A5/ja
Priority to JP2022036450A priority Critical patent/JP7472183B2/ja
Application granted granted Critical
Publication of JP7039582B2 publication Critical patent/JP7039582B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019523779A 2016-11-03 2017-11-02 活性化可能な抗ｃｔｌａ－４抗体およびその使用 Active JP7039582B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022036450A JP7472183B2 (ja) 2016-11-03 2022-03-09 活性化可能な抗ｃｔｌａ－４抗体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662417212P 2016-11-03 2016-11-03
US62/417,212 2016-11-03
PCT/US2017/059740 WO2018085555A1 (en) 2016-11-03 2017-11-02 Activatable anti-ctla-4 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022036450A Division JP7472183B2 (ja) 2016-11-03 2022-03-09 活性化可能な抗ｃｔｌａ－４抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2020500016A JP2020500016A (ja) 2020-01-09
JP2020500016A5 JP2020500016A5 (enExample) 2020-12-10
JP7039582B2 true JP7039582B2 (ja) 2022-03-22

Family

ID=61132883

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019523779A Active JP7039582B2 (ja) 2016-11-03 2017-11-02 活性化可能な抗ｃｔｌａ－４抗体およびその使用
JP2022036450A Active JP7472183B2 (ja) 2016-11-03 2022-03-09 活性化可能な抗ｃｔｌａ－４抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022036450A Active JP7472183B2 (ja) 2016-11-03 2022-03-09 活性化可能な抗ｃｔｌａ－４抗体およびその使用

Country Status (20)

Country Link
US (2) US11117968B2 (enExample)
EP (1) EP3535300B1 (enExample)
JP (2) JP7039582B2 (enExample)
KR (2) KR102584340B1 (enExample)
CN (1) CN110072890B (enExample)
AR (1) AR110678A1 (enExample)
AU (1) AU2017355446A1 (enExample)
BR (1) BR112019008223A2 (enExample)
CA (1) CA3042679A1 (enExample)
CL (1) CL2019001226A1 (enExample)
CO (1) CO2019004469A2 (enExample)
EA (1) EA201990875A1 (enExample)
ES (1) ES3053667T3 (enExample)
IL (1) IL265625A (enExample)
MX (1) MX2019004775A (enExample)
MY (1) MY200695A (enExample)
PE (1) PE20191131A1 (enExample)
SG (1) SG11201902857SA (enExample)
TW (2) TW202334213A (enExample)
WO (1) WO2018085555A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2715232C2 (ru) 2013-09-25 2020-02-26 Сайтомкс Терапьютикс, Инк. Субстраты матриксной металлопротеиназы и другие расщипляемые фрагменты и способы их использования
ES3057033T3 (en) 2014-01-31 2026-02-25 Cytomx Therapeutics Inc Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
WO2018085555A1 (en) 2016-11-03 2018-05-11 Bristol-Myers Squibb Company Activatable anti-ctla-4 antibodies and uses thereof
TWI776827B (zh) 2016-11-28 2022-09-11 日商中外製藥股份有限公司 能夠調節配體結合活性的配體結合分子
TW202323287A (zh) 2016-11-28 2023-06-16 日商中外製藥股份有限公司 包含抗原結合域與運送部分的多胜肽
JP7173993B2 (ja) 2017-05-19 2022-11-17 ウーシー バイオロジクス（シャンハイ）カンパニー リミテッド 細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対する新規モノクローナル抗体
KR102771546B1 (ko) 2017-11-08 2025-02-21 야페이 상하이 바이오로지 메디신 사이언스 앤드 테크놀로지 컴퍼니 리미티드 생체분자의 컨쥬게이트 및 이의 용도
MX2020005220A (es) * 2017-11-28 2020-08-24 Chugai Pharmaceutical Co Ltd Polipeptido que incluye dominio de union al antigeno y seccion de transporte.
US12195528B2 (en) 2017-11-28 2025-01-14 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand-binding activity
JP2021518603A (ja) 2018-03-20 2021-08-02 シートムエックス セラピューティクス，インコーポレイテッド 哺乳動物対象における活性化可能抗体種の定量薬理学モデリングのためのシステムおよび方法
EP3794023A1 (en) 2018-05-14 2021-03-24 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
DK3794024T5 (da) 2018-05-14 2024-08-19 Werewolf Therapeutics Inc Aktiverbare interleukin-2 polypeptider og fremgangsmåder til anvendelse heraf
WO2019230867A1 (en) 2018-05-30 2019-12-05 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprising aggrecan binding domain and carrying moiety
KR20210141447A (ko) 2018-12-26 2021-11-23 실리오 디벨럽먼트, 인크. 항-ctla4 항체 및 이의 사용 방법
CN113631189A (zh) 2019-03-13 2021-11-09 默沙东公司 包含ctla-4和pd-1封闭剂的抗癌联合治疗
JP7720785B2 (ja) 2019-04-18 2025-08-08 ブリストル－マイヤーズ スクイブ カンパニー 低ｐＨで結合するために特異性が増強されたイピリムマブバリアント
MX2021013766A (es) 2019-05-14 2022-02-21 Werewolf Therapeutics Inc Restos de separacion y metodos de uso de los mismos.
CN110498856B (zh) * 2019-09-17 2020-08-11 浙江玉安康瑞生物科技有限公司 一种ctla-4单克隆抗体5h7及其用于抗肿瘤的用途
CN115942973A (zh) 2019-11-08 2023-04-07 百时美施贵宝公司 用于黑色素瘤的lag-3拮抗剂疗法
JP2023510108A (ja) 2019-12-19 2023-03-13 ブリストル－マイヤーズ スクイブ カンパニー Ｄｇｋ阻害剤およびチェックポイントアンタゴニストの組み合わせ
US20210301015A1 (en) * 2020-01-17 2021-09-30 Aetio Biotherapy, Inc. Pro-antibody that reduces off-target toxicity
EP4126955A4 (en) * 2020-03-26 2024-08-07 Aetio Biotherapy, Inc. BISPECIFIC FUSION PROTEINS FOR DEPLETION OF REGULATORY T CELLS
CA3172641A1 (en) * 2020-04-01 2021-10-07 Xilio Development, Inc. Masked il-12 cytokines and their cleavage products
MX2022011780A (es) * 2020-04-09 2022-11-10 Cytomx Therapeutics Inc Composiciones que contienen anticuerpos activables.
AR122043A1 (es) * 2020-05-12 2022-08-03 Bristol Myers Squibb Co Dosificación y administración del anticuerpo anti-ctla-4 activable
CN115803343A (zh) * 2020-05-26 2023-03-14 百奥泰生物制药股份有限公司 多特异性抗体及其应用
JP7681681B2 (ja) 2020-08-11 2025-05-22 ジャナックス セラピューティクス，インク． 切断可能リンカー組成物および方法
US11555078B2 (en) 2020-12-09 2023-01-17 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting PSMA and effector cell antigens
TW202246324A (zh) * 2021-03-01 2022-12-01 美商艾希利歐發展股份有限公司 用於治療癌症的經掩蔽之ｃｔｌａ４及ｐｄ１／ｐｄｌ１抗體之組合
US20250332251A1 (en) 2021-06-21 2025-10-30 Bristol-Myers Squibb Company Use of sucrose, mannitol and glycine to reduce reconstitution time of high concentration lyophilized biologics drug products
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
US20250333539A1 (en) 2022-03-23 2025-10-30 Cytomx Therapeutics, Inc. Activatable antigen-binding protein constructs and uses of the same
US20250333487A1 (en) 2022-03-25 2025-10-30 Cytomx Therapeutics, Inc. Activatable dual-anchored masked molecules and methods of use thereof
WO2023192973A1 (en) 2022-04-01 2023-10-05 Cytomx Therapeutics, Inc. Activatable multispecific molecules and methods of use thereof
EP4504782A2 (en) 2022-04-01 2025-02-12 CytomX Therapeutics, Inc. Cd3-binding proteins and methods of use thereof
US20260042840A1 (en) 2022-04-07 2026-02-12 Bristol-Myers Squibb Company Methods of treating tumor
WO2024030850A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable substrates and methods of use thereof
WO2024030845A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
AR130080A1 (es) 2022-08-01 2024-10-30 Cytomx Therapeutics Inc Restos escindibles por proteasas, y métodos de uso de los mismos
AR130076A1 (es) 2022-08-01 2024-10-30 Cytomx Therapeutics Inc Restos escindibles por proteasas, y métodos de uso de los mismos
WO2024030858A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable substrates and methods of use thereof
WO2024031032A1 (en) 2022-08-05 2024-02-08 Bristol-Myers Squibb Company Anti-ctla-4 antibodies for treatment of kras mutant cancers
WO2024049203A1 (ko) * 2022-09-02 2024-03-07 주식회사 시클리드 항 ctla-4 모노클로날 항체 및 이의 용도
CN120958015A (zh) 2023-04-12 2025-11-14 西托姆克斯治疗公司 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法
EP4694934A1 (en) 2023-04-12 2026-02-18 CytomX Therapeutics, Inc. Masking polypeptides, activatable cytokine constructs, and related compositions and methods
WO2024216170A2 (en) 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
TW202540188A (zh) 2023-12-01 2025-10-16 比利時商艾伯霖克斯公司 精準活化的多肽
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
US12521446B2 (en) 2024-02-27 2026-01-13 Bristol-Myers Squibb Company Anti-CEACAM5 antibody drug conjugates
WO2025240659A2 (en) 2024-05-14 2025-11-20 Cytomx Therapeutics, Inc. Activatable constructs, compositions and methods
WO2026020161A1 (en) 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods
WO2026024841A1 (en) 2024-07-24 2026-01-29 Astellas Us Llc Bispecific antibodies that bind cd3 and muc1 and methods of use thereof
WO2026035650A2 (en) 2024-08-05 2026-02-12 Cytomx Therapeutics, Inc. Cleavable polypeptides and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010536370A (ja) 2007-08-22 2010-12-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
JP2012514982A (ja) 2009-01-12 2012-07-05 サイトムエックス セラピューティクス，エルエルシー 改変した抗体組成物、それを作製および使用する方法
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
JP2016520614A (ja) 2013-05-28 2016-07-14 ディーシービー−ユーエスエー エルエルシーＤｃｂ−Ｕｓａ Ｌｌｃ タンパク質薬物の不活性化のための抗体ロッカー
WO2016149201A2 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
WO2001014557A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
NZ517202A (en) * 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2001091798A2 (en) 2000-06-01 2001-12-06 Universite Catholique De Louvain Tumor activated prodrug compounds
AU9399501A (en) 2000-10-09 2002-04-22 Isis Innovation Therapeutic antibodies
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
CN102911987B (zh) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 基因组被修饰的细胞
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
WO2004021861A2 (en) 2002-09-03 2004-03-18 Vit Lauermann Targeted release
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
WO2006089231A2 (en) 2005-02-18 2006-08-24 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
US7666817B2 (en) 2005-08-31 2010-02-23 The Regents Of The University Of California Cellular libraries of peptide sequences (CLiPS) and methods of using the same
WO2007084672A2 (en) 2006-01-17 2007-07-26 Medarex, Inc. Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
US20090220529A1 (en) 2006-03-10 2009-09-03 Diatos, S.A. Anticancer Drugs Conjugated to Antibody via an Enzyme Cleavable Linker
JP2010507394A (ja) 2006-10-24 2010-03-11 トルービオン ファーマスーティカルズ インコーポレイテッド 改良免疫糖タンパク質のための物質および方法
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
US8293685B2 (en) 2007-07-26 2012-10-23 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
EP2240204A1 (en) 2008-02-04 2010-10-20 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
ES2458541T5 (en) 2008-05-02 2025-08-04 Seagen Inc Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
KR20190089048A (ko) * 2011-02-15 2019-07-29 이뮤노젠 아이엔씨 컨쥬게이트의 제조방법
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
US8852599B2 (en) * 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
MX2014013041A (es) 2012-04-27 2015-03-19 Cytomx Therapeutics Inc Anticuerpos activables que se ligan al receptor del factor de crecimiento epidermico y metodos de uso de los mismos.
US9212224B2 (en) 2012-05-15 2015-12-15 Bristol-Myers Squibb Company Antibodies that bind PD-L1 and uses thereof
CN104736168B (zh) 2012-05-31 2018-09-21 索伦托治疗有限公司 与pd-l1结合的抗原结合蛋白
WO2013192550A2 (en) 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
WO2014089113A1 (en) * 2012-12-03 2014-06-12 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
KR102243062B1 (ko) 2013-05-02 2021-04-21 아납티스바이오, 아이엔씨. 예정된 사멸-1에 대한 항체
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
JP6623353B2 (ja) 2013-09-13 2019-12-25 ベイジーン スウィッツァーランド ゲーエムベーハー 抗ｐｄ−１抗体並びにその治療及び診断のための使用
US11046975B2 (en) 2013-10-07 2021-06-29 Prestige Biopharma Pte. Ltd. Bicistronic expression vector for antibody expression and method for producing antibody using same
ES2746805T3 (es) 2013-12-12 2020-03-06 Shanghai hengrui pharmaceutical co ltd Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
ES2716685T3 (es) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
US10414814B2 (en) 2014-07-03 2019-09-17 City Of Hope Tumor-selective CTLA-4 antagonists
CA3175979A1 (en) 2014-12-22 2016-06-30 Pd-1 Acquisition Group, Llc Anti-pd-1 antibodies
WO2016115275A1 (en) 2015-01-13 2016-07-21 City Of Hope Ctla4-binding protein peptide-linker masks
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
US10696745B2 (en) 2015-06-11 2020-06-30 Wuxi Biologics (Shanghai) Co. Ltd. Anti-PD-L1 antibodies
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
MY187739A (en) 2015-08-11 2021-10-18 Wuxi Biologics Cayman Inc Novel anti-pd-1 antibodies
WO2017024515A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
EA201891178A1 (ru) 2015-12-14 2019-01-31 Макродженикс, Инк. Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
CA3008287A1 (en) 2016-01-11 2017-07-20 Armo Biosciences, Inc. Interleukin-10 in production of antigen-specific cd8+ t cells and methods of use of same
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2018085555A1 (en) 2016-11-03 2018-05-11 Bristol-Myers Squibb Company Activatable anti-ctla-4 antibodies and uses thereof
EP3625253A4 (en) 2017-05-16 2021-03-24 Scalmibio, Inc. ACTIVABLE ANTIBODIES AND THEIR METHODS OF USE
EP3668545A2 (en) 2017-08-16 2020-06-24 Bristol-Myers Squibb Company Prodruggable antibodies, prodrugs thereof, and methods of use and making

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010536370A (ja) 2007-08-22 2010-12-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
JP2012514982A (ja) 2009-01-12 2012-07-05 サイトムエックス セラピューティクス，エルエルシー 改変した抗体組成物、それを作製および使用する方法
JP2016520614A (ja) 2013-05-28 2016-07-14 ディーシービー−ユーエスエー エルエルシーＤｃｂ−Ｕｓａ Ｌｌｃ タンパク質薬物の不活性化のための抗体ロッカー
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
WO2016149201A2 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof

Also Published As

Publication number Publication date
CL2019001226A1 (es) 2019-09-13
SG11201902857SA (en) 2019-05-30
JP7472183B2 (ja) 2024-04-22
AU2017355446A1 (en) 2019-05-02
CN110072890B (zh) 2022-11-29
US11117968B2 (en) 2021-09-14
PE20191131A1 (es) 2019-09-02
EP3535300B1 (en) 2025-10-22
EA201990875A1 (ru) 2019-09-30
CN110072890A (zh) 2019-07-30
KR20230141941A (ko) 2023-10-10
US20220089734A1 (en) 2022-03-24
IL265625A (en) 2019-05-30
MY200695A (en) 2024-01-11
AR110678A1 (es) 2019-04-24
WO2018085555A1 (en) 2018-05-11
TW202334213A (zh) 2023-09-01
US20190359714A1 (en) 2019-11-28
KR102814027B1 (ko) 2025-05-27
TWI784983B (zh) 2022-12-01
MX2019004775A (es) 2019-08-05
KR20190072626A (ko) 2019-06-25
EP3535300A1 (en) 2019-09-11
ES3053667T3 (en) 2026-01-23
KR102584340B1 (ko) 2023-10-10
CA3042679A1 (en) 2018-05-11
TW201819412A (zh) 2018-06-01
WO2018085555A8 (en) 2018-05-31
JP2022091800A (ja) 2022-06-21
CO2019004469A2 (es) 2019-05-10
US12441799B2 (en) 2025-10-14
JP2020500016A (ja) 2020-01-09
BR112019008223A2 (pt) 2019-07-16

Similar Documents

Publication Publication Date Title
JP7472183B2 (ja) 活性化可能な抗ｃｔｌａ－４抗体およびその使用
JP7351845B2 (ja) Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
RU2733315C2 (ru) Комбинированная терапия для лечения злокачественной опухоли
US20220048996A1 (en) Antibody molecules that bind cd137 and ox40
US20250043003A1 (en) Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
CN114874331A (zh) 治疗性抗体和它们的用途
JP2022529939A (ja) 低ｐＨで結合するために特異性が増強されたイピリムマブバリアント
WO2015188047A1 (en) ANTI-CD-137 MONOCLONAL ANTIBODIES WITH DISTINCT FcγR BINDING ABILITIES FOR TREATMENT OF CANCER OR AUTOIMMUNITY
JP2024539650A (ja) 活性化可能なポリペプチド複合体
KR20240111823A (ko) 항-cd47 항체 및 이의 사용 방법
US20260028405A1 (en) Anti-cd16a antibodies and methods of use thereof
TW201625301A (zh) 藉由ｆｏｌｒ１標靶藥及葉酸代謝拮抗劑用於癌症患者之治療方法與醫藥
CA3209364A1 (en) Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
US20250243283A1 (en) Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
EA043382B1 (ru) Активируемые антитела против ctla-4 и их применение
HK1258304A1 (en) Optimized anti-cd3 bispecific antibodies and uses thereof
HK1258304B (en) Optimized anti-cd3 bispecific antibodies and uses thereof
EA040594B1 (ru) Оптимизированные биспецифические анти-cd3 антитела и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220105

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220309

R150 Certificate of patent or registration of utility model

Ref document number: 7039582

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250